Efficacy and safety of Entrectinib in patients with NTRK-fusion positive solid tumors: updated integrated analysis
NTRK gene fusions lead to transcription of chimeric TRK proteins with overexpressed kinase function.
Entrectinib ( Rozlytrek ) is a potent inhibitor of TRKA/B/C. In phase 1/2 studies ( ALKA, STARTRK-1, STARTRK-2; EudraCT 2012-000148-88; NCT02097810; NCT02568267 ), Entrectinib was effective in patients with NTRK-fusion positive solid tumors.
Researchers have presented updated data in a larger population with longer follow-up.
In this integrated analysis of adult patients from 3 phase 1/2 trials ( data cut-off 31 Oct 2018 ), tumors were assessed by blinded independent central review ( BICR ) with RECIST v1.1 ( end of cycle 1; then every 8 weeks ).
Primary endpoints were overall response rate ( ORR ) and duration of response ( DOR ). Secondary endpoints were progression-free survival ( PFS ), overall survival ( OS ), efficacy in patients with/without baseline CNS disease, and safety.
There were 74 evaluable patients with advanced / metastatic NTRK-fp solid tumors.
Median duration of survival follow-up in all patients was 14.2 months ( range 0.1–29.7 ).
BICR ORR was 63.5% ( 95% CI 51.5–74.4 ), with 5 complete responses ( 6.8% ).
Median BICR DOR was 12.9 months ( 95% CI 9.3–NE ); median BICR PFS was 11.2 months ( 95% CI 8.0–15.7 ); median OS was 23.9 months ( 16.0–NE ).
In patients with no baseline CNS disease ( investigator-assessed; n=55 ), BICR ORR was 65.5% ( 95% CI 51.4–77.8 ) and median BICR DOR in responders was 12.9 months ( 95% CI 9.3–NE ).
In patients with baseline CNS disease ( investigator-assessed; n=19 ), BICR ORR was 57.9% ( 95% CI 33.5–79.8 ) and median BICR DOR in responders was 6.0 months ( 95% CI 4.2–NE ).
Safety was in line with that previously reported; the most common grade 3 or more treatment-related adverse effects were weight gain ( 8, 7.1% ), anemia ( 8, 7.1% ), and fatigue ( 7, 6.2% ).
In conclusion, in this updated analysis, including more patients and longer follow-up, Entrectinib continued to demonstrate clinically meaningful responses in patients with NTRK-fusion positive solid tumors, with and without baseline CNS disease. ( Xagena )
Fonte: American Society of Clinical Oncology ( ASCO ) Virtual Meeting, 2020
The FDA ( Food and Drug Administration ) has granted accelerated approval to Monjuvi ( Tafasitamab-cxix, Tafasitamab ), a CD19-directed...
Enfortumab vedotin in urothelial cancer: durable responses in patients who had previously received immunotherapy but were ineligible for Cisplatin in locally advanced or metastatic setting
The results from the second cohort of patients in the pivotal phase 2 single-arm clinical trial known as EV-201, were...
Opdivo plus Yervoy for patients with hepatocellular carcinoma previously treated with Sorafenib, FDA approved
Opdivo ( Nivolumab ) 1 mg/kg plus Yervoy ( Ipilimumab ) 3 mg/kg ( injections for intravenous use ) was...
The rapid spread of Coronavirus disease 2019 ( COVID-19 ) caused by severe acute respiratory syndrome coronavirus 2 ( SARS-CoV-2...
Rubraca as monotherapy treatment for patients with BRCA1/2-mutant, metastatic castration-resistant prostate cancer, treated with androgen receptor-directed therapy and a taxane-based chemotherapy
The FDA ( U.S. Food and Drug Administration ) has approved Rubraca ( Rucaparib ) tablets for the treatment...
Olaparib in patients with pancreatic cancer with BRCA1/2 inactivating mutations: results from TAPUR study
TAPUR ( Targeted Agent and Profiling Utilization Registry ) is a phase II basket study evaluating anti-tumor activity of targeted...
Cemiplimab ( Libtayo ) monotherapy achieves clinically meaningful activity in patients with advanced cutaneous squamous cell carcinoma ( CSCC )...
Camrelizumab is a fully humanized, monoclonal antibody against PD-1. A study has assessed the efficacy and safety of Camrelizumab plus...
Reblozyl for the treatment of transfusion-dependent anemia in adult patients with myelodysplastic syndromes or beta thalassemia, approved in European Union
The European Commission ( EC ) has approved Reblozyl ( Luspatercept ) for the treatment of: a) adult patients with transfusion-dependent...